Abstract:Introduction Cellular senescence, defined as irreversible cell-cycle arrest, is closely connected with age and has also been associated with Mild Cognitive Impairment (MCI). Changes in the cellular secretome pattern, known as Senescence-Associated Secretory Phenotype (SASP), can be measured as a marker of cellular senescence. Higher SASP indices have been associated with Major Depressive Disorders (MDD) and the combination of remitted MDD (rMDD) and MCI (but neither group alone). Apathy, characterized by diminished goal-directed behaviour, is present in 11%-45% of patients with MCI. Apathy is associated with increased risk of progression from MCI to dementia, but the neurobiology underlying this remains unknown. We sought to investigate SASP markers in patients with MCI (without MDD) or remitted major depressive disorder (rMDD) (with or without MCI) and compared those with and without apathy to better understand the neurobiology of this neuropsychiatric symptom. Methods The PACt-MD study (Preventing Alzheimer's dementia with cognitive remediation plus transcranial direct current stimulation in mild cognitive impairment or depression) was a randomized controlled trial that evaluated the efficacy and tolerability of combining cognitive remediation and transcranial direct current stimulation to slow cognitive decline in three groups: MCI only, rMDD only (rMDD-MCI), or both (rMDD+MCI). At baseline, the Neuropsychiatric Inventory Questionnaire apathy (NPI-Q-A), completed by the care partner, assessed apathy presence (Yes/No) as well as severity (Mild=1, Moderate=2, Severe=3). The SASP index (SASP-I), composed of 22 circulating plasma proteins, measured senescence at baseline. Two-way ANCOVA compared main and interaction effects of NPI-Q-A (presence or absence) and diagnostic groups (MCI only, rMDD-MCI, rMDD+MCI) on SASP-I. Within diagnostic groups, one-way ANCOVAs were conducted on NPI-Q-A presence and SASP-I. Chi-square test was conducted to assess apathy severity between groups. To evaluate specificity for apathy, linear regressions between total NPI-Q score and SASP index were conducted to assess associations between total neuropsychiatric symptoms (NPS) and SASP-I scores. Age, sex, medical comorbidity burden (measured using Cumulative Illness Rating Scale- Geriatrics), and depression severity (measured using Montgomery-Asberg Depression Rating Scale) were a priori covariates chosen based on literature. Results 281 participants ((mean (SD) age 71.6 (6.2) yrs; 180 (64.1%) female; apathy severity 0.25 (0.61)) completed the NPI-Q-A and SASP-I at baseline (MCI: 125; rMDD-MCI: 60; rMDD+MCI: 96). The numbers of participants who endorsed apathy within groups were MCI: 18 (14.4%); rMDD-MCI: 8 (13.3%); rMDD+MCI: 20 (20.8%). Apathy severity did not differ between groups ((x2 (6) = 4.05, p=0.670)). There was a group by NPI-Q-A interaction F (2, 264) = 3.836, p = .023)). Within rMDD+MCI, the SASP-I was higher in apathetic vs. nonapathetic ((F (1, 88) = 7.303, p = .008)), with no differences between those with and without apathy in other groups. Linear regression analysis showed no significant associations between total NPI-Q scores and SASP index in each group; adjusted values for each group as follows (MCI: β= -0.098, p= 0.257; rMDD-MCI: β=-0.189, p=0.213; rMDD+MCI: β=0.198, p=0.066). Conclusions In this analysis, the SASP-I was associated with apathy only in participants with rMDD+MCI, but not in each group alone. While consistent with previous literature that apathy predicts cognitive decline, it suggests a different underlying mechanism, involving cellular aging that may be at play particularly in those with both MCI and rMDD. Longitudinal studies on apathy, cognitive decline, and changes in SASP are needed to understand the interaction between aging and the biological mechanisms underlying apathy in these populations.

P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial

P105: Measuring clinically relevant change in apathy symptoms in ADMET 2

Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2

P4-308: Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild to moderate Alzheimer's disease: A phase ii multicenter randomized controlled trial

Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial

Relative lack of cognitive effects of methylphenidate in elderly male volunteers

Neural markers of methylphenidate response in children with attention deficit hyperactivity disorder and the impact on executive function

Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: a Network Meta-Analysis Protocol

Citalopram for agitation in Alzheimer's disease: design and methods

Senescence Markers and Apathy Symptoms in Patients with Mild Cognitive Impairment and/or Remitted Major Depression: An Analysis of the PACt-MD Study

Apathy and Affective Symptoms Associated with Elevated Alzheimers Disease Biomarkers

Efficacy and safety of neuromodulation for apathy in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials

Predictors of Methylphenidate response in children and adolescents with ADHD: the role of sleep disturbances

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

Neuropsychiatric Symptom Profile in Alzheimer's Disease and Their Relationship With Functional Decline

Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder

Disease modification is not all — we need symptomatic therapies for Alzheimer disease

Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes

Efficacy of Brexpiprazole Across Agitation Behaviors in Alzheimer's Disease, Including Impact on Caregivers, Analyzed Using the Neuropsychiatric Inventory: A Post Hoc Pooled Analysis of Randomized, Fixed-Dose, Placebo-Controlled Trials

A Positron Emission Tomography Study of Nigro-Striatal Dopaminergic Mechanisms Underlying Attention: Implications for ADHD and Its Treatment.